Phenylpiracetam Hydrazide

Phenylpiracetam Hydrazide, also marketed as fonturacetam hydrazide, is a chemically modified analogue of phenylpiracetam (phenotropil, carphedon), a potent member of the racetam family of nootropics ^[1][4]. Structurally it retains the 4-phenyl-2-pyrrolidinone core of phenylpiracetam but replaces the terminal acetamide group with a hydrazide functional group, meaning a carbonyl bound to a nitrogen-nitrogen moiety in place of the simple amide ^[4][6]. This is a deliberate medicinal-chemistry style modification of the parent scaffold, and it defines the compound's identity as a distinct research chemical rather than an established drug ^[4].

It is important to state plainly that phenylpiracetam hydrazide itself has essentially no dedicated peer-reviewed pharmacological or clinical literature; it has not been characterized in published human trials, and descriptions of its effects are extrapolated from the phenylpiracetam family to which it belongs rather than from direct study of the hydrazide ^[1][4]. What can be described is the pharmacology of the parent. Phenylpiracetam is a chiral racetam whose enantiomers act on the dopamine transporter, with the S-form identified as a selective DAT inhibitor and DAT the only significant molecular target in radioligand profiling ^[2][3]. In behavioral studies phenylpiracetam increases locomotor activity, produces antidepressant-like effects, and improves memory in a stereospecific manner, and it is credited with enhancing physical endurance and resistance to cold ^[1][5].

One relevant clue to how a hydrazide substitution changes racetam activity comes from older work on piracetam derivatives, which found that inserting a hydrazide group into the piracetam molecule shifted its immunological activity toward stimulation of antibody formation, in contrast to the immunosuppression seen when a phenyl radical was added ^[6]. Phenylpiracetam hydrazide is not an approved medicine anywhere and is sold internationally only as a research chemical or nootropic powder, placing it within the broad, loosely regulated category of unauthorized nootropic ingredients that regulators and anti-doping bodies have scrutinized ^[4]. It is typically encountered as a crystalline powder under the names phenylpiracetam hydrazide or fonturacetam hydrazide ^[4].

Being honest, there is essentially no human safety data for phenylpiracetam hydrazide; it is sold as a research chemical with no clinical track record of its own. The hydrazide chemistry is worth a note of caution, since some hydrazides carry liver or nerve concerns, though that has not been studied for this compound specifically. Anecdotally the effects are mild, and the reported gripes are the usual stimulant style ones: possible insomnia if taken late, some irritability, or a light headache. As a close relative of phenylpiracetam it would also raise the same red flag in drug tested sport. With so little known, treat it as an obscure curiosity, keep doses conservative, and do not assume it is as benign as the parent.

Phenylpiracetam hydrazide, sometimes called fonturacetam hydrazide, is a structural variant of phenylpiracetam in which the racetam's amide group is replaced by a hydrazide. It arose from the research-chemical sphere as a next-generation twist on one of the most potent racetams rather than from a documented pharmaceutical development program, and there is no published record of its discovery, synthesis history, or clinical development. Its identity and rationale are inferred almost entirely from the phenylpiracetam parent it is built upon. It is sold strictly as a research chemical and has never been evaluated or approved as a drug.

Interest in phenylpiracetam hydrazide flows directly from the respected phenylpiracetam framework, a scaffold known for selective dopamine transporter inhibition and stimulant-like focus, endurance, and cold resistance. Enthusiasts are drawn to the idea that a small structural change might tune that profile, and vendors present it as a novel iteration on a proven design. The essential and honest caveat is that its own pharmacology has not been characterized in any published human or animal study, so its potency, dopaminergic activity, and safety remain uncharacterized. Notably, work on other piracetam derivatives shows that swapping an amide for a hydrazide can meaningfully change biological activity, so it should not be assumed identical to its parent; it is best treated as a genuinely uncharted research compound.